Madison Based Exact Sciences News Today

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

A company developing a rival colon cancer test, which was sued by Exact Sciences in November over alleged patent infringement, has asked for a review of the patent.

A company developing a rival colon cancer test, which was sued by Exact Sciences in November over alleged patent infringement, has asked for a review of the patent.

A company developing a rival colon cancer test, which was sued by Exact Sciences in November over alleged patent infringement, has asked for a review of the patent.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported third-quarter net income of $0.8 million, or $0.00 per share, on revenue of $628 million.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported third-quarter net income of $0.8 million, or $0.00 per share, on revenue of $628 million.

The biomedical giant best known for its Cologuard test reported a second-quarter loss of $81 million, or 45 cents per share, on revenue of $622.1 million.